» Articles » PMID: 8630374

Regulation of Thrombopoietin Levels by C-mpl-mediated Binding to Platelets

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1996 Mar 15
PMID 8630374
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

The involvement of platelets and the c-mpl receptor in the regulation of thrombopoietin (TPO) plasma concentrations and tissue mRNA levels was investigated in both normal mice and mice defective in c-mpl (c-mpl-/-). Although c-mpl-/- mice have fewer platelets and higher plasma TPO activity than normal mice, there was no increase in TPO mRNA levels as measured by an S1 nuclease protection assay. After the intravenous injection of 125I-TPO, specific uptake of radioactivity by the spleen and blood cells was present in the normal mice, but absent in the c-mpl-/- mice. Platelet-rich plasma (PRP) from normal mice was able to bind and internalize 125I-TPO, whereas PRP from c-mpl-/- mice lacked this ability. Analysis of 125I-TPO binding to normal PRP indicated that binding was specific and saturable, with an approximate affinity of 560 pmol/L and 220 receptors per platelet. PRP from normal mice was also able to degrade 125I-TPO into lower molecular weight fragments. After the intravenous injections, c-mpl-/- mice cleared a dose of 125I-TPO at a much slower rate than did normal mice. Injection of washed platelets from normal mice into c-mpl-/- mice resulted in a dramatic, but transient, decrease in plasma TPO levels. These data provide evidence that platelets regulate plasma TPO levels via binding to the c-mpl receptor on circulating platelets.

Citing Articles

LMAN1 serves as a cargo receptor for thrombopoietin.

Everett L, Lin Z, Friedman A, Tang V, Myers G, Balbin-Cuesta G JCI Insight. 2024; 9(24).

PMID: 39499573 PMC: 11665562. DOI: 10.1172/jci.insight.175704.


Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.

Johnson B, Cheng L, Koenitzer J, Catlett I, Schafer P Front Immunol. 2024; 15:1437512.

PMID: 39403378 PMC: 11472182. DOI: 10.3389/fimmu.2024.1437512.


Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review.

Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I Immunotargets Ther. 2024; 13:461-486.

PMID: 39290805 PMC: 11407319. DOI: 10.2147/ITT.S463384.


Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasms.

Kaur A, Venkatesan A, Kandarpa M, Talpaz M, Raghavan M Blood Adv. 2024; 8(13):3372-3387.

PMID: 38640435 PMC: 11255115. DOI: 10.1182/bloodadvances.2023011432.


Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease.

Behrens K, Kauppi M, Viney E, Kueh A, Hyland C, Willson T Leukemia. 2024; 38(6):1342-1352.

PMID: 38491305 PMC: 11147766. DOI: 10.1038/s41375-024-02219-5.